Reported 22 days ago
iTeos Therapeutics, Inc. (NASDAQ: ITOS), a clinical-stage biopharmaceutical company, has faced significant stock losses, including a 33.36% drop over the past year. Following disappointing results from a Clinical Phase 2 study, the company announced a review of strategic alternatives to enhance shareholder value. Despite its potential, the firm is not favored among hedge funds, as investor focus has shifted towards AI stocks that promise higher returns.
Source: YAHOO